Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Merck's Keytruda: A Remarkable Science-To-Success Story

This article was originally published in Scrip

Executive Summary

With the probability of a drug making it from discovery to FDA approval extremely low – with some estimates putting the success rate at only one in every 5,000 – the story of how Merck's checkpoint inhibitor Keytruda (pembrolizumab) came to the marketplace is nothing short of remarkable.



Related Companies